SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Pediatric Oncology Nursing
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Norville, R.
Right arrow Articles by Cheshire, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Norville, R.
Right arrow Articles by Cheshire, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Virus-Specific Cytotoxic T Lymphocytes as Prophylaxis for Epstein-Barr Virus Lymphoproliferative Disease in Pediatric Bone Marrow Transplant Recipients

Robbie Norville, RN, MSN, OCN, CPON

Bone Marrow Transplant Unit, St Jude Children's Research Hospital, Memphis, TN

Donna Nance, RN, BSN

Bone Marrow Transplant Unit, St Jude Children's Research Hospital, Memphis, TN

Shannon Cheshire, RN, BSN

Bone Marrow Transplant Unit, St Jude Children's Research Hospital, Memphis, TN

Epstein-Barr virus lymphoproliferative disease (EBV LPD) is a well-recognized, life-threatening complication of bone marrow transplantation (BMT). The incidence of EBV LPD is increasing as more transplants are performed from mismatched and unrelated donors. Significant strides have been made in the diagnosis, prevention, and treatment of EBV LPD in marrow transplant recipients. Immunovirological assays can provide early identification of patients at risk for developing EBV LPD. Prophylaxis and treatment by the adoptive transfer of EBV-specific T cells and the subsequent long-term restoration of immunity against EBV-associated lymphoproliferation have provided positive outcomes in the management of this uniformly fatal complication of BMT. The purpose of this article is to provide a review of EBV LPD and to present a newly developed strategy for EBV LPD prophylaxis in pediatric BMT recipients.

Journal of Pediatric Oncology Nursing, Vol. 14, No. 4, 194-201 (1997)
DOI: 10.1177/104345429701400403
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement